Recent advances in the development of high precision nucleic acid therapies have put cures in reach for previously untreatable diseases and conditions. Therapies in development have the potential to eradicate genetic diseases, block cancer and reverse aging.
However, these therapies all face the same challenge; delivery of genetic payloads directly into target cells with no significant toxicity. Gene therapy-clinical trials using cationic or ionizable lipid nanoparticle platforms have been disappointing due to high toxicity and an inability to target organs other than the liver.
Fusogenix is formulated with well-tolerated neutral lipids and our proprietary FAST proteins (Fusion-Associated Small Transmembrane) that ensues highly efficient fusion and intracellular delivery of therapeutic nucleic acid payloads. Our Fusogenix platform combines the favorable low-toxicity profile of a neutral lipid formulation with the high efficacy of our fusogenic protein-mediated delivery technology.
Entos developed a library of Fusogenix formulations to effectively deliver a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi and CRISPR. The classes of health indications that can be addressed by Fusogenix is unlimited. Currently, Entos is involved in Oncology Therapeutics, DNA Vaccines, Anti-Virals, Gene Editing, Immunotherapy, and Senolytic therapies.
Fusogenix is safe and well tolerated at doses that far exceed the expected human efficacious dose. Tolerability studies show no adverse pathology, either within the principle uptake organs or the liver and spleen, even at very high doses.
Due to its favorable tolerability profile, Fusogenix has significant bioavailability in a wide variety of extra-hepatic tissues. This enables the delivery of therapeutic doses of nucleic acid medicines throughout the body.
Fusogenix is non-immunogenic, which allows for repeat dosing with no reduction in efficacy. These qualities make our platform ideal for long term treatment of healthy individuals.
Entos utilizes a scalable microfluidic manufacturing process that allows for continuous production of highly homogeneous, reproducible, clinical grade material. Our high capacity single-step method enables the production of GMP drug substances with unprecedented precision.
Fusogenix formulated with targeted FAST proteins can preferentially accumulate in tissues where they have maximum therapeutic impact.
Fusogenix uses a novel mechanism of action to deliver nucleic acids, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi, siRNA, and CRISPR.
We strive to be active partners in the upcoming transformation of healthcare with the development of innovative genetic personalized medicines.